Currentblue cross blue shield - tennesseePolicy N/A

Cardiovascular Disease Risk Assessment

Defines coverage criteria and limitations for laboratory and biomarker tests used in cardiovascular disease (CVD) risk assessment for adults, including frequency and indications for lipid panels, apolipoprotein B, lipoprotein(a), hs-CRP, and lists tests that do not meet coverage.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyCardiovascular Disease Risk Assessment

Policy CodePolicy N/A

Change TypeNo material change

Effective Date

Next Review Date

Key ActionClinicians should use 2013 ACC/AHA PCEs to calculate 10-year risk of CVD events to determine increased risk and applicability of annual lipid testing or hs-CRP when risk-based treatment decisions are uncertain.

POLICY UPDATE CHANGES

No material clinical or coverage changes — the brief indicates no material changes to policy.

3Tests explicitly covered (lipid panel, apoB, Lp(a))

10Tests explicitly not covered (listed categories)

2013Guideline year referenced for PCEs

5Key biomarker thresholds listed

3Proprietary advanced tests listed (examples)

Coverage Summary

This policy defines coverage criteria and limitations for laboratory and biomarker tests used in adult cardiovascular disease (CVD) risk assessment, including frequency and indications for testing and explicit non‑coverage statements. Headline tests that MEET COVERAGE CRITERIA are: a simple lipid panel (total cholesterol, HDL‑C, LDL‑C, triglycerides), apolipoprotein B (apoB) in specified clinical situations, and one‑time lifetime measurement of lipoprotein(a) (Lp(a)) for adults ≥18 years. The policy takes a mixed stance overall: certain core tests and targeted biomarker use are covered when guideline‑based indications are met, while many novel or advanced biomarker tests and multianalyte risk panels are explicitly NOT covered. The brief enumerates 3 tests explicitly covered (lipid panel, apoB, Lp(a)) and lists 10 categories/tests that do not meet coverage. Guideline sources referenced include the 2013 ACC/AHA Pooled Cohort Equations for risk estimation and multiple major society guidelines (eg, ACC/AHA 2018/2019 cholesterol guidance, 2019 ESC/EAS, AACE/AACE statements, USPSTF, CCS) cited throughout the policy.

Key thresholds & quick facts

Policy subjectCardiovascular Disease Risk Assessment testing

StatusCURRENT

Guideline year referenced for PCEs2013 (ACC/AHA Pooled Cohort Equations)

Policy Summary

Payerblue cross blue shield - tennessee

PolicyCardiovascular Disease Risk Assessment

Policy CodePolicy N/A

Change TypeNo material change

Effective Date

Next Review Date

On This Page

Medical-Necessity Criteria

Lipid panel coverage (individuals ≥18 years)

Lipid panel testing MEETS COVERAGE CRITERIA when ANY of the following conditions apply:

ANY of the following

Screening intervals: To screen for cardiovascular disease (CVD): every 4 years for individuals ages 18 to 79 years.
Increased-risk annual screening: To screen for cardiovascular disease (CVD): annually for individuals at increased risk for cardiovascular disease as defined by 2013 ACC/AHA Pooled Cohort Equations (PCEs) to calculate 10-year risk of CVD events.
Annual screening for specified conditions: Annually for individuals at an increased risk of dyslipidemia due to specified conditions (examples include obesity or metabolic syndrome; nephrotic syndrome; hypothyroidism; hyperthyroidism; pancreatitis; diabetes; chronic kidney disease; Cushing syndrome; pregnancy; cholestatic liver disease; lipid metabolism disorders such as Gaucher disease in adults).
Statin therapy monitoring - baseline: For individuals about to begin or currently receiving statin therapy: to establish baseline levels before initiating statin therapy.
Statin therapy monitoring - after initiation/change: For individuals about to begin or currently receiving statin therapy: every 4 to 12 weeks after initiation or change of therapy.
Statin therapy monitoring - stable: For individuals about to begin or currently receiving statin therapy: annually when no medication changes have occurred.
Long-term drug therapy monitoring: Annually for individuals on a long-term drug therapy that requires lipid monitoring (example: Accutane, antipsychotics).
HIV/ART monitoring - baseline: For HIV positive individuals about to begin or currently receiving antiretroviral therapy (ART): to establish baseline levels before initiating ART.
HIV/ART monitoring - after initiation/change: For HIV positive individuals about to begin or currently receiving ART: every 1 to 3 months after initiation or change of therapy.
HIV/ART monitoring - stable: For HIV positive individuals about to begin or currently receiving ART: every 6 to 12 months when no medication changes have occurred.

Apolipoprotein B (apoB)

Measurement of apoB MEETS COVERAGE CRITERIA for ANY of the following situations:

ANY of the following

ApoB indications: Individuals with hypertriglyceridemia.
ApoB indications: Individuals with diabetes mellitus.
ApoB indications: Individuals with obesity or metabolic syndrome.
ApoB indications: Individuals with other dyslipidemias (such as very low LDL-C).

Lipoprotein(a) (Lp(a))

Measurement of Lp(a) MEETS COVERAGE CRITERIA:

ALL of the following

Age criterion: For individuals 18 years of age or older
Frequency: Once per lifetime

High-sensitivity C-reactive protein (hs-CRP)

hs-CRP MEETS COVERAGE CRITERIA for risk-based decision uncertainty after quantitative risk assessment using ACC/AHA PCEs when performed as:

hs-CRP protocol

Initial screening: two measurements at least two weeks apart.
Follow-up screening: If the initial screen was abnormal: follow-up screening allowed up to once per year.

Tests not meeting coverage criteria

The following DO NOT MEET COVERAGE CRITERIA:

ANY of the following

Not covered: All other cardiovascular disease risk assessments not described above: testing for CRP (traditional CRP) does not meet coverage.
Not covered: Measurement of high-sensitivity cardiac troponin T (hs-cTnT) for outpatient CVD risk assessment and stratification.
Not covered: Homocysteine testing for CVD risk assessment, screening, evaluation, and management.
Not covered: Measurement of novel lipid and non-lipid biomarkers (e.g., apolipoprotein AI, apolipoprotein E, B-type natriuretic peptide, cystatin C, fibrinogen, leptin, LDL subclass, HDL subclass).

Guideline-Identified Considerations & Appropriate Use

Guideline-identified risk-enhancing biomarker considerations

Biomarker measurement may be reasonable/considered in specific clinical scenarios as identified by guideline sources:

Measurement may be reasonable when ONE of the following applies

Family history of premature ASCVD (males <55 y; females <65 y)
Severe hypercholesterolemia: Primary severe hypercholesterolemia (LDL ≥190 mg/dL) or suspected familial hypercholesterolemia
Premature ASCVD: Individuals with premature ASCVD (males <55 y; females <65 y) particularly without traditional risk factors
Borderline/intermediate risk: Individuals with intermediate (7.5%-19.9%) or borderline (5%-7.4%) 10-y ASCVD risk when decision about statin is uncertain
Less-than-anticipated LDL response: Less-than-anticipated LDL-C lowering despite good adherence to therapy
Family history Lp(a): Family history of elevated Lp(a)
Aortic stenosis: Calcific valvular aortic stenosis
Recurrent ASCVD: Recurrent or progressive ASCVD despite optimal lipid-lowering therapy
Very high risk for PCSK9 consideration: Very high risk individuals to better define PCSK9 inhibitor candidates (history of multiple major ASCVD events or one major event plus multiple high-risk conditions)

CDC/AHA hs-CRP recommendation

hs-CRP measurement guidance from CDC/AHA workshop findings:

CDC/AHA hs-CRP guidance

Assay limitation and averaging: Limit current assays of inflammatory markers to hs-CRP measured twice, either fasting or nonfasting, with the average expressed in mg/L
Timing: Two measurements optimally occur two weeks apart
If abnormal: If results are abnormal, repeat hs-CRP and examine for sources of infection or inflammation
Population screening: Do not screen entire adult population for hs-CRP as a public health measure; consider hs-CRP as an adjunct in patients with 10-year CHD risk ~10%-20%

CMS monitoring frequency for lipid testing (2005 NCD summary)

When monitoring long-term anti-lipid therapy or following borderline high cholesterol:

CMS monitoring frequency

Annual reasonable: Annual lipid panel is reasonable for monitoring long-term dietary or pharmacologic therapy
First year frequency: Any one component of the panel or a measured LDL may be medically necessary up to six times in the first year for monitoring therapy
More frequent testing indication: More frequent testing may be indicated for marked elevations or changes to anti-lipid therapy due to inadequate response
After goals achieved: After treatment goals achieved, LDL or total cholesterol may be measured three times yearly

CDC Lipids Standardization Program (LSP) guidance

Laboratory quality and standardization:

LSP standardization: LSP provides blinded reference samples for TC, TG, HDL-C, apo A-I, and apo B; labs accurate receive CDC certification

ACC/AHA and other society biomarker thresholds and recommendations

Selected numeric thresholds and measurement recommendations cited:

Numeric thresholds and timing

Hypertriglyceridemia threshold: Persistently elevated primary hypertriglyceridemia ≥175 mg/dL is a risk-enhancing factor≥175 mg/dL
hs-CRP threshold: Elevated hs-CRP ≥2 mg/L noted as a risk-enhancing factor (ACC)≥2 mg/L
Lp(a) thresholds: Elevated Lp(a) ≥50 mg/dL or ≥125 nmol/L is a risk-enhancing factor≥50 mg/dL or ≥125 nmol/L

Cardiovascular disease is highly prevalent and costly: the AHA 2024 update reports approximately 127.9 million people in the U.S. with some form of CVD and estimated direct and indirect costs of about $422.3 billion. Traditional risk assessment relies on clinical risk factors and lipid panels, but up to ~20% of CVD events may be missed by standard algorithms, prompting evaluation of additional biomarkers.

Reviewed biomarkers include apolipoproteins and related lipoprotein measures (apoB, apoA‑I, apoE, LDL/HDL subclasses, IDL/remnant cholesterol), cardiac markers (BNP/NT‑proBNP, high‑sensitivity cardiac troponins), inflammatory markers (hs‑CRP, fibrinogen, Lp‑PLA2), metabolic markers (cystatin C, leptin, homocysteine), and nutritional markers such as long‑chain omega‑3 fatty acids). Evidence summarized in the policy shows modest associations for many of these markers but limited incremental predictive value for routine population screening; apoB and Lp(a) have targeted roles in select clinical situations, while many novel biomarkers and expanded proprietary multianalyte panels generally add limited actionable benefit.

General Coverage Principles and Appropriate Use

Covered or recommended testing when meeting guideline-backed indications:

General coverage principles

Baseline lipid profile (total cholesterol, HDL-C, non-HDL, triglycerides) should be taken before treatment and used for CVD risk estimation.
LDL-C primary: LDL-C recommended as the primary lipid analysis for diagnosis, management, screening, and risk estimation.
ApoB recommendation: ApoB analysis recommended for risk assessment, particularly in persons with high triglycerides, diabetes, obesity/metabolic syndrome, or very low LDL-C; may be used as an alternative to LDL-C and preferred over non-HDL-C in specified circumstances.
Lp(a) lifetime: Lp(a) measurement: consider at least once in a person's lifetime to identify very high inherited levels (>180 mg/dL / >430 nmol/L); may assist in familial risk assessment but is not a routine repeat monitoring target.>180 mg/dL (>430 nmol/L)
Novel biomarkers not routine: Routine assessment of novel biomarkers (eg, Apo C-III) is not recommended for CV risk stratification.
CAC use: CAC score assessment by CT may be helpful for treatment decisions in moderate-risk patients and to inform shared decision-making when statin initiation is uncertain, but routine use is not recommended for all.
ABI/carotid: ABI and carotid/femoral plaque assessment by ultrasound may be informative for risk reclassification when CAC not available.
Limited value biomarkers: High-sensitivity cardiac troponin, hsCRP, fibrinogen, and other circulating biomarkers generally provide limited incremental value for population-level risk stratification; may have niche predictive value in select populations.
Advanced panels discouraged: Expanded/advanced lipid panels (particle sizing, NMR, VAP, Liposcale®, other proprietary multianalyte risk algorithms) are generally not recommended for routine screening; ASCP recommends against routine ordering of expanded lipid panels.
Diabetes specifics: For patients with diabetes, routine microalbuminuria assessment and resting ECG in certain contexts are recommended; lipid panels and 10-year ASCVD risk calculation are recommended.
Repeat interval: many societies recommend repeating overall risk assessment every 5 years for adults (more often for higher risk).Every 5 years
Special populations: postpartum women with pregnancy complications should have a comprehensive lipid panel at least 12 weeks postpartum; HIV-infected patients: fasting lipid profile prior to and within 1-3 months after ART initiation and every 6-12 months if abnormal (or every 5 years if normal).12 weeks postpartum; 1-3 months; 6-12 months; 5 years

Tests Not Routinely Recommended / Discouraged

Tests recommended against routine use or with insufficient evidence:

Discouraged tests

Apo C-III: Routine measurement of Apo C-III is not recommended (use unknown).
Novel biomarkers: Routine use of circulating or urinary novel biomarkers for CVD risk stratification is not recommended due to limited additional value.
USPSTF ECG: USPSTF: recommends against screening with resting or exercise ECG in low-risk adults to prevent CVD (grade D); insufficient evidence to recommend ECG in intermediate/high-risk asymptomatic adults (I).
VA/DoD suggest against routine CAC testing and against routine use of additional risk markers (hsCRP, ABI, CAC) for risk assessment.

Coding

Applicable CPT/HCPCS procedure codesmixed

No codes listed

No specific billing codes listed in this partmixed

No codes listed

Covered / commonly referenced CPT codes for lipid and biomarker testingCPTCovered

80061	Lipid panel
82172	Apolipoprotein, each
82465	Cholesterol, serum or whole blood, total
83718	Lipoprotein, direct measurement; HDL cholesterol
83719	Lipoprotein, direct measurement; VLDL cholesterol
83721	Lipoprotein, direct measurement; LDL cholesterol
83722	Lipoprotein, direct measurement; small dense LDL cholesterol
84478	Triglycerides
86140	C-reactive protein
86141	C-reactive protein; high sensitivity (hsCRP)

1–10 of 24

1/3

Proprietary / specific multianalyte and advanced test codes (often proprietary, restricted use)CPT

0019M	SOMAmer® - Cardiovascular disease plasma protein biomarkers, algorithmic 4-year likelihood (SomaLogic)
0052U	VAP Cholesterol Test - high resolution fractionation by vertical auto profile (VAP Diagnostics)
0308U	HART CAD® - 3 protein algorithm for obstructive CAD (Atlas Genomics)
0309U	HART CVE® - 4 protein algorithm for MACE risk (Atlas Genomics)
0377U	Liposcale® - NMR-based advanced lipoprotein profile (CIMA Sciences, LLC)
0415U	SmartHealth Vascular Dx™ - multianalyte algorithm for ACS 5-year score (Morningstar Laboratories) - note: described as deleted risk

Provider Actions & Billing Rules

Documentation Required

Use of ACC/AHA Pooled Cohort Equations (PCEs)

Use the 2013 ACC/AHA Pooled Cohort Equations (PCEs) to calculate 10-year CVD risk and determine who meets criteria for annual lipid testing or where adjunct testing such as hs‑CRP may be helpful in uncertain treatment decisions. Apply clinician–patient risk discussion to individualize risk based on the PCE estimate and risk‑enhancing factors.

Documentation Required

Lipid monitoring intervals for therapies

Obtain baseline lipid levels prior to initiating statin therapy or antiretroviral therapy (ART). For statins: reassess 4–12 weeks after initiation or dose change and then annually when stable. For ART: obtain baseline, then every 1–3 months after initiation or change, and every 6–12 months when stable.

Documentation Required

Indications for apoB and Lp(a) testing

Order apoB for patients with hypertriglyceridemia, diabetes, obesity/metabolic syndrome, other dyslipidemias (eg very low LDL‑C), when on lipid therapy, or when familial dysbetalipoproteinemia/familial combined hyperlipidemia is suspected. Measure Lp(a) once in a lifetime for adults (≥18 years) when indicated to identify very high inherited levels that may alter lifetime ASCVD risk.

Documentation Required

hs-CRP measurement protocol

When hs‑CRP is used to inform risk when treatment decisions are uncertain, obtain two measurements optimally two weeks apart, express the average in mg/L, and if initial results are abnormal repeat testing and evaluate for sources of infection or inflammation.

Documentation Required

Lipid monitoring frequency (CMS guidance)

Per CMS guidance for monitoring long‑term anti‑lipid therapy: perform an annual lipid panel for monitoring; in the first year up to six measurements of any one panel component or measured LDL may be medically necessary for therapy monitoring; increase testing frequency for marked elevations or changes to therapy; after goals achieved LDL or total cholesterol may be measured up to three times yearly.

Documentation Required

Use of advanced lipid testing

Advanced lipoprotein testing (eg, apoB, LDL‑P, remnant cholesterol) may be considered selectively to guide therapy in specified patients (eg, high triglycerides, diabetes, obesity). Use standardized methods when available and prefer laboratories participating in CDC standardization programs.

Documentation Required

Baseline lipid testing prior to treatment

Obtain a baseline lipid profile (total cholesterol, HDL‑C, non‑HDL‑C, triglycerides) prior to initiating lipid‑lowering therapy.

80061
82465
83718
84478

Documentation Required

ApoB measurement in specified contexts

Measure apolipoprotein B (ApoB) in contexts such as elevated triglycerides, diabetes, obesity/metabolic syndrome, very low LDL‑C, during lipid therapy, or when familial dyslipidemia is suspected; ApoB can be used as an alternative primary measurement in selected patients.

82172

Prior Authorization

Advanced/proprietary multianalyte or NMR testing

Proprietary multianalyte, NMR, or other advanced/commercial algorithms (examples: Liposcale®, VAP, SOMAmer®, HART tests) are generally not recommended for routine screening and may be subject to payer justification or prior authorization; these assays often correspond to specific CPT/HCPCS proprietary codes.

0377U
0052U
0019M
0308U
0309U

Documentation Required

Lp(a) one-time measurement

Measure Lp(a) at least once in an adult's lifetime (adult ≥18 years) when indicated to detect very high inherited levels that may impact lifetime ASCVD risk.

83695

Billing Rule

Procedure codes referenced for policy purposes

The procedure codes listed in this policy are provided for reference only. They are not exhaustive and do not establish coverage or billing rules; follow payer billing guidelines and local coverage determinations for appropriate use and frequency.

80061
81599
82172
83695
0377U
0052U

Evidence Summary & Thresholds

Key evidence points summarized: the AHA 2024 statistics quantify the national burden and economic impact of CVD (≈127.9 million affected; ≈$422.3 billion in costs).

High‑sensitivity cardiac troponins show associations with future CVD and mortality in cohort studies (examples: highest quartile hs‑troponin I ≥5.2 ng/L HR ≈2.3; elevated hs‑cTnI associated with mortality HR ≈2.38 and incident CVD HR ≈3.41 in older adults), but outpatient use for routine risk stratification is not covered.

Lp‑PLA2 is an independent predictor of CVD in observational studies, yet clinical trials of Lp‑PLA2 inhibitors failed to demonstrate improved patient outcomes, limiting its role for routine risk assessment.

Long‑chain omega‑3 (EPA/DHA) trial evidence is mixed — some trials report reduced CVD events while others do not; guideline advice supports omega‑3 supplementation only in select patients with prevalent CHD or heart failure, and routine measurement of omega‑3 levels is not supported.

Guideline consensus supports baseline lipid panels for risk estimation and selective use of apoB and Lp(a) in defined scenarios (eg, high TG, diabetes, familial risk), whereas many novel biomarkers and advanced lipoprotein profiling generally provide limited incremental value for routine screening. Notable guidelines referenced include the 2013 ACC/AHA PCEs, 2018/2019 ACC/AHA cholesterol guidelines, 2019 ESC/EAS dyslipidemia guidance, AACE/ACE statements, CDC/AHA hs‑CRP workshop, USPSTF statements, and CCS recommendations.

Specific biomarker thresholds

hs-CRP≥2.0 mg/L (high-sensitivity CRP considered a risk-enhancing factor)

Triglycerides (primary hypertriglyceridemia)≥175 mg/dL (persistently elevated; risk-enhancing)

ApoB≥130 mg/dL (risk-enhancing; corresponds to LDL‑C ≥160 mg/dL)

Lp(a) — risk-enhancing cutoffs≥50 mg/dL or ≥125 nmol/L (constitutes a risk-enhancing factor)

Lp(a) — very high inherited level (ESC/EAS)>180 mg/dL (>430 nmol/L) (identify once in lifetime to detect very high inherited levels)

Definitions

Simple lipid panel: a blood panel composed of total cholesterol, HDL‑C, LDL‑C, and triglycerides; calculated ratios (eg, total/HDL) may be reported. Other tests (apolipoproteins, particle number/size, Lp(a)) are not components of a simple lipid profile.

PCEs (Pooled Cohort Equations): the 2013 ACC/AHA Pooled Cohort Equations used to calculate 10‑year risk of atherosclerotic CVD events and to determine individuals who may need annual lipid testing or adjunctive biomarker assessment when treatment decisions are uncertain.

Non‑HDL‑C: defined as total cholesterol minus HDL‑C; includes VLDL and IDL (fasting) and VLDL, IDL, and chylomicron remnants (non‑fasting).

Remnant cholesterol / IDL: the cholesterol content of triglyceride‑rich lipoproteins (VLDL and IDL fasting; VLDL, IDL, chylomicron remnants non‑fasting); elevated remnant cholesterol is associated with CVD risk.

hs‑CRP: high‑sensitivity C‑reactive protein, an inflammatory marker measured in mg/L; CDC/AHA recommend measuring hs‑CRP twice ~two weeks apart and averaging results when used as an adjunct for risk assessment.

Lp(a): lipoprotein(a), a genetically determined LDL‑like particle associated with inherited ASCVD risk; very high levels are considered >180 mg/dL (>430 nmol/L) per ESC and risk‑enhancing thresholds include ≥50 mg/dL (≥125 nmol/L).

ApoB: apolipoprotein B, a marker reflecting atherogenic particle number, recommended especially when triglycerides are high or LDL‑C is very low; an ApoB ≥130 mg/dL is a risk‑enhancing threshold corresponding approximately to LDL‑C ≥160 mg/dL.

OpenPayer

Cardiovascular Disease Risk Assessment

Coverage Summary

Medical-Necessity Criteria

Guideline-Identified Considerations & Appropriate Use

General Coverage Principles and Appropriate Use

Coding

Provider Actions & Billing Rules

Evidence Summary & Thresholds

Definitions

Medicare Determinations

Revision History

effective	name	number	type
2005
CMS lipid monitoring guidance (summary)

NCD